Illumina, Inc.  

(Public, NASDAQ:ILMN)   Watch this stock  
Find more results for ILMN
-7.33 (-5.11%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 134.54 - 143.13
52 week 130.00 - 242.37
Open 142.66
Vol / Avg. 2.25M/1.80M
Mkt cap 19.92B
P/E 43.94
Div/yield     -
EPS 3.10
Shares 146.40M
Beta 0.81
Inst. own 102%
Apr 19, 2016
Q1 2016 Illumina Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 2, 2016
Q4 2015 Illumina Inc Earnings Call - Webcast
Feb 2, 2016
Q4 2015 Illumina Inc Earnings Release
Jan 11, 2016
Illumina Inc at JPMorgan Healthcare Conference - Webcast
Jan 10, 2016
Illumina Inc Investor Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Jan '16) 2016
Net profit margin 17.39% 20.61%
Operating margin 24.34% 27.61%
EBITD margin - 30.13%
Return on average assets 11.12% 13.02%
Return on average equity 22.14% 27.88%
Employees 3,700 -
CDP Score - -


5200 Illumina Way
SAN DIEGO, CA 92122-4616
United States - Map
+1-858-2024500 (Phone)
+1-858-2024766 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.

Officers and directors

Jay T. Flatley Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Francis A. deSouza President, Director
Age: 44
Bio & Compensation  - Reuters
Marc A. Stapley Chief Financial Officer, Executive Vice President, Chief Administrative Officer
Age: 45
Bio & Compensation  - Reuters
David R. Walt Ph.D. Chairman - Scientific Advisory Board, Independent Director
Age: 62
Bio & Compensation  - Reuters
Christian O. Henry Chief Commercial Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Tristan B. Orpin Executive Vice President - Clinical Genomics
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Omead Ostadan Executive Vice President - Operations, Products and Strategy
Bio & Compensation  - Reuters
Mostafa Ronaghi Ph.D. Chief Technology Officer, Senior Vice President
Age: 46
Bio & Compensation  - Reuters
Charles E Dadswell Senior Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
Sanjay Chikarmane Senior Vice President, General Manager
Bio & Compensation  - Reuters